Altimmune, Inc.
ALT
$2.91
-$0.02-0.68%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 26.00K | 5.00K | 5.00K | 5.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 26.00K | 5.00K | 5.00K | 5.00K |
| Cost of Revenue | 16.19M | 18.41M | 14.96M | 17.24M | 15.83M |
| Gross Profit | -16.19M | -18.38M | -14.96M | -17.23M | -15.82M |
| SG&A Expenses | 8.05M | 10.51M | 5.90M | 5.69M | 5.99M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.24M | 28.92M | 20.86M | 22.93M | 21.82M |
| Operating Income | -24.24M | -28.89M | -20.86M | -22.92M | -21.82M |
| Income Before Tax | -22.56M | -27.36M | -19.01M | -22.15M | -20.26M |
| Income Tax Expenses | -- | 0.00 | -- | -- | -681.00K |
| Earnings from Continuing Operations | -22.56M | -27.36M | -19.01M | -22.15M | -19.58M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.56M | -27.36M | -19.01M | -22.15M | -19.58M |
| EBIT | -24.24M | -28.89M | -20.86M | -22.92M | -21.82M |
| EBITDA | -24.22M | -28.87M | -20.83M | -22.89M | -21.79M |
| EPS Basic | -0.18 | -0.27 | -0.21 | -0.27 | -0.26 |
| Normalized Basic EPS | -0.11 | -0.17 | -0.13 | -0.17 | -0.17 |
| EPS Diluted | -0.18 | -0.27 | -0.21 | -0.27 | -0.26 |
| Normalized Diluted EPS | -0.11 | -0.17 | -0.13 | -0.17 | -0.17 |
| Average Basic Shares Outstanding | 124.46M | 100.61M | 89.42M | 81.48M | 75.55M |
| Average Diluted Shares Outstanding | 124.46M | 100.61M | 89.42M | 81.48M | 75.55M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |